BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29474933)

  • 1. An optimised multi-arm multi-stage clinical trial design for unknown variance.
    Grayling MJ; Wason JMS; Mander AP
    Contemp Clin Trials; 2018 Apr; 67():116-120. PubMed ID: 29474933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the impact of efficacy stopping rules on the error rates under the multi-arm multi-stage framework.
    Blenkinsop A; Parmar MK; Choodari-Oskooei B
    Clin Trials; 2019 Apr; 16(2):132-141. PubMed ID: 30648428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-arm multi-stage (MAMS) randomised selection designs: impact of treatment selection rules on the operating characteristics.
    Choodari-Oskooei B; Blenkinsop A; Handley K; Pinkney T; Parmar MKB
    BMC Med Res Methodol; 2024 Jun; 24(1):124. PubMed ID: 38831421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes.
    Bratton DJ; Parmar MK; Phillips PP; Choodari-Oskooei B
    Trials; 2016 Jul; 17(1):309. PubMed ID: 27369182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Group sequential multi-arm multi-stage survival trial design with treatment selection.
    Wu J; Li Y
    J Biopharm Stat; 2024 Jul; 34(4):453-468. PubMed ID: 37455424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlling the family-wise error rate in multi-arm, multi-stage trials.
    Crouch LA; Dodd LE; Proschan MA
    Clin Trials; 2017 Jun; 14(3):237-245. PubMed ID: 28545335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Group sequential designs for stepped-wedge cluster randomised trials.
    Grayling MJ; Wason JM; Mander AP
    Clin Trials; 2017 Oct; 14(5):507-517. PubMed ID: 28653550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Group sequential t-test for clinical trials with small sample sizes across stages.
    Shao J; Feng H
    Contemp Clin Trials; 2007 Sep; 28(5):563-71. PubMed ID: 17434814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (II): sample size re-estimation.
    Tamhane AC; Wu Y; Mehta CR
    Stat Med; 2012 Aug; 31(19):2041-54. PubMed ID: 22733687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A web application for the design of multi-arm clinical trials.
    Grayling MJ; Wason JM
    BMC Cancer; 2020 Jan; 20(1):80. PubMed ID: 32005187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choice of futility boundaries for group sequential designs with two endpoints.
    Schüler S; Kieser M; Rauch G
    BMC Med Res Methodol; 2017 Aug; 17(1):119. PubMed ID: 28789615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses.
    Chen LM; Ibrahim JG; Chu H
    J Biopharm Stat; 2014; 24(4):817-33. PubMed ID: 24697500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-stage optimal designs based on exact variance for a single-arm trial with survival endpoints.
    Shan G
    J Biopharm Stat; 2020 Sep; 30(5):797-805. PubMed ID: 32129130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection.
    Jaki T; Hampson LV
    Stat Med; 2016 Feb; 35(4):522-33. PubMed ID: 26456537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adding new experimental arms to randomised clinical trials: Impact on error rates.
    Choodari-Oskooei B; Bratton DJ; Gannon MR; Meade AM; Sydes MR; Parmar MK
    Clin Trials; 2020 Jun; 17(3):273-284. PubMed ID: 32063029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.
    Royston P; Barthel FM; Parmar MK; Choodari-Oskooei B; Isham V
    Trials; 2011 Mar; 12():81. PubMed ID: 21418571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-arm trials with multiple primary endpoints and missing values.
    Hasler M; Hothorn LA
    Stat Med; 2018 Feb; 37(5):710-721. PubMed ID: 29108137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Some recommendations for multi-arm multi-stage trials.
    Wason J; Magirr D; Law M; Jaki T
    Stat Methods Med Res; 2016 Apr; 25(2):716-27. PubMed ID: 23242385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal design of multi-arm multi-stage trials.
    Wason JM; Jaki T
    Stat Med; 2012 Dec; 31(30):4269-79. PubMed ID: 22826199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.